Displaying 1 - 73 of 73 tests
AML Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79, CD11b, CD123, CD34, CD45, CD117, cMPO, and nTdT (10 markers).

Flow Cytometry
AML Favorable-Risk PanelProbes: RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16)
Disease(s): Acute myeloid leukemia
Probes may be ordered separately.
FISH
AML FISH Panel (New York)

Probes: 5q-, -5 (5p15.2, 5q33-34) | 7q-, -7 (7q31, Cen 7) | Trisomy 8 (Cen 8) | MLL (11q23) | RUNX1T1/RUNX1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16)
Probes may be ordered separately.
Disease(s): AML
Note: STAT processing is available by request for PML-RARA. Note STAT along with MD contact name and phone number to receive STAT results.

FISH
AML Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are cCD3, CD11b, CD13, CD14, CD16, CD19, cCD22, CD33, CD34, CD45, CD64, cCD79a, CD117, CD123, HLA-DR, cMPO, and nTdT (17 markers).

Flow Cytometry
AML Non-Favorable Risk FISH Panel

Probes: RPN1, MECOM (3q21, 3q26.2) | 5q-, -5 (5p15, 5q31, 5q33 | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | DEK/NUP214 (CAN) t(6;9) | MLL (11q23) | ETV6 (12p13) | 17p- (TP53 17p13.1, NF1 17q11.2) | Probes may be ordered separately.
Disease(s):Acute myeloid leukemia

FISH
AML Reflex PanelRoutine cytogenetics with automatic addition of the NeoTYPE™ AML Prognostic Profile when cytogenetics results show intermediate risk including normal cytogenetics, +6, +8, -Y, or del(12p). Molecular
AML Standard FISH Panel

Probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | MLL (11q23) | 20q- (20q12, 20qter) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16)
Probes may be ordered separately except +8 and 20q- which are combined.
Disease(s): Acute myeloid leukemia Probes may be ordered separately except +8 and 20q- which are combined.
Note: STAT processing is available by request for PML-RARA. Note STAT along with MD contact name and phone number to receive STAT results.

FISH
ASXL1 Mutation Analysis

Bi-directional sequencing of the majority of exons 13 and 14 of ASXL1, corresponding to amino acids 406-1396.

Molecular
CBFB inv(16)Probes: CBFB inv(16), t(16;16)
Disease(s): AML, AMML (AML-M4E)
FISH
CBL Mutation Analysis

Bi-directional sequencing of exons 8 and 9 of the CBL gene.

Molecular
CD11cIn normal cells, CD11c is expressed on activated CD4/CD8+ T cells, granulocytes, lymphocytes, macrophages, and NK cells.

In diseased, cells, CD11c is detected on acute myeloid leukemia (AML)-M4 and M5, hairy cell leukemia, lymphoplasmacytic lymphoma (81%), small lymphocytic lymphoma (SLL), splenic lymphoma, Langerhans cell histiocytosis, sinus histiocytosis, psoriatic skin lesions, and some follicular lymphomas.
Immunohistochemistry (IHC)
CD123CD123 labels plasmacytoid dendritic cells and is useful in diagnosing neoplasms derived from these cells as well as reactive conditions, such as histiocytic necrotizing lymphadentis. Immunohistochemistry (IHC)
CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3. Immunohistochemistry (IHC)
CD33CD33 is a useful marker to identify cells of myeloid and monocytic lineage, leukemias and myeloproliferative neoplasms derived from these cells. Immunohistochemistry (IHC)
CD34CD34, a single chain transmembrane glycoprotein, is selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells and endothelial cells. CD34 antibody labels many gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans, solitary fibrous tumor and a subset of sarcomas. CD34 staining has been also used to measure angiogenesis. Immunohistochemistry (IHC)
CD61CD61 (GPIIIa) is a glycoprotein found on megakaryocytes, platelets, and their precursors. CD61 antigen plays a role in platelet aggregation and also as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectrin. This antibody is useful in detecting neoplastic platelet precursors, normal platelets, and most cases of megakaryocytic leukemias. Immunohistochemistry (IHC)
CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells. Immunohistochemistry (IHC)
Chromosome Analysis

A wide variety of abnormalities can be identified, providing both diagnostic and prognostic information. Acute leukemias, lymphomas and chronic myeloid and lymphoid disorders are examined cytogenetically in order to establish the exact nature of the acquired genetic change. Rearrangements, also known as translocations, inversions, and deletions, can usually be detected under a light microscope. In most leukemias and lymphomas, changes in chromosome number (ploidy) or chromosome structure (rearrangements) are often observed.
 

Cytogenetics
DNMT3A Mutation Analysis

Bi-directional sequencing of exon 26, a mutation hotspot region containing R882 and other mutations. In hematological disease, testing may be performed on plamsa to increase sensitivity. For solid tumors, tumor enrichment is performed before extraction.

Molecular
Erythroid-Mega Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD41, cCD61, CD13, CD34, CD45, CD71,  CD117, and CD235a (8 markers).

Flow Cytometry
ETV6 Mutation Analysis

Bi-directional sequencing of exons 2-7 of the ETV6 gene (formerly called TEL). This assay detects sequence variants rather than ETV6 translocations.

Molecular
ETV6-RUNX1 (TEL-AML1) Translocation, t(12;21)

Real-time RT-PCR for quantitative detection of the t(12;21) ETV6-RUNX1 fusion transcript (formerly called TEL-AML1). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results are reported as a percentage ratio between quantities of transcript of t(12;21) and the sum of t(12;21) plus a control gene.

Molecular
EZH2 Mutation Analysis

Bi-directional sequencing of exons 3-13 and 15-18 of the EZH2 gene.

Molecular
FLT3 Mutation Analysis

Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bi-directional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as percent abnormal ITD peak. Testing may be performed on plasma to increase sensitivity.

Molecular
Glycophorin AGlycophorin A (sialoglycoprotein alpha) is one of two transmembrane proteins exposed on the outer surface of normal human erythrocytes. This monoclonal antibody reacts with an epitope located on the extracellular domain of glycophorin A and does not cross-react with glycophorin D (glycophorin delta). In normal human erythrocytes, glycophorin A is expressed during all stages of differentiation, from the normoblast to the mature erythrocyte. Once maximally expressed, the quantity of glycophorin A in each red blood cell remains constant. Glycophorin A has also been located in the blast cells of cases of erythroleukemia. Cases of acute lymphoblastic and myeloblastic leukemia are not reactive. Immunohistochemistry (IHC)
Hemoglobin AHemoglobin A antibody reacts with the alpha chain of adult hemoglobin A. This antibody is useful in the detection of red blood cell precursors. Immunohistochemical localization of hemoglobin is excellent as an erythroid marker for the detection of immature, dysplastic, and megaloblastic erythroid cells in myeloproliferative disorders, such as erythroleukemia. In contrast, myeloid cells, lymphoid cells, plasma cells, histiocytes, and megakaryocytes stain negative with anti-hemoglobin A. Anti-hemoglobin A, combined with antibodies against CD34, CD117, CD68, and MPO can be helpful in distinguishing between reactive extramedullary hematopoiesis and that seen in neoplastic myeloid disorders in spleen. Anti-hemoglobin A is limited to expression by erythroid precursors in bone marrow and is therefore of assistance in calculating percentages of erythroid precursors. Immunohistochemistry (IHC)
HLADRThis antibody to the humn leukocyte antigen (HLA) MHC class II surface antigen stains a variety of cells expressing the HLADR antigen including B-lymphocytes, macrophages and dendritic cells. HLADR antibody is useful in the differentiation of lymphomas and leukemias and it discriminates most B-cell derived lymphomas from those of T-cell origin. Immunohistochemistry (IHC)
IDH1 & IDH2 Mutation Analysis

Bi-directional sequencing of the exon 4 mutation hotspot regions in both the IDH1 and IDH2 genes. IDH1 and IDH2 are analyzed concurrently. In hematological disease, testing may be performed on plasma to increase sensitivity. For solid tumors, tumor enrichment is performed before extraction.

Molecular
inv(16), CBFB-MYH11 Translocation

Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript. Positive results are reported as ratio of the amount of fusion transcript with the amount of transcript from a normal control gene. This assay identifies type A fusions, which account for >90%. Analytical sensitivity is 1 tumor cell in 100,000 normal cells.

Molecular
Ki67

Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.

Immunohistochemistry (IHC)
LysozymeLysozyme is synthesized predominantly in reactive histiocytes rather than in resting, unstimulated phagocytes. This antibody labels myeloid cells, histiocytes, granulocytes, macrophages and monocytes. It is helpful in the identification of myeloid or monocytic nature of acute leukemia. Immunohistochemistry (IHC)
MET (c-MET) Mutation Analysis

Bi-directional Sanger sequencing of MET is performed using PCR primers designed to target hotspot mutations in exons 14, 16, 17 and 19.

Molecular
MLL (11q23)Probes: MLL (11q23)
Disease(s): ALL, AML
FISH
MPOMyeloperoxidase (MPO) is an important enzyme used by granulocytes during phagocytic lysis of engulfed foreign particles. In normal tissues and in a variety of myeloproliferative disorders, myeloid cells of both neutrophilic and eosinophilic types, at all stages of maturation, exhibit strong cytoplasmic reactivity for MPO. MPO is useful in differentiating between myeloid and lymphoid leukemias. Immunohistochemistry (IHC)
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Molecular
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Cytogenetics
NeoLAB™ AML Profile - Liquid Biopsy

This test is performed by sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53 and WT1. Test orders include summary interpretation of all results together. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoLAB™ MDS/CMML Profile- Liquid Biopsy.

Molecular
NeoLAB™ FLT3 Mutation Analysis - Liquid Biopsy

Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bidirectional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as percent abnormal ITD peak. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ IDH1 Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH1 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ IDH2 Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH2 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ inv(16), CBFB-MYH11 Translocation - Liquid Biopsy

Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript using cell-free plasma DNA/RNA. This assay identifies type A fusions, which account for >90%

Molecular
NeoLAB™ KIT (c-KIT) Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ KRAS Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ KRAS Mutation Analysis- Liquid Biopsy will only be performed for hematological diseases at this time.

Molecular
NeoLAB™ Myeloid Disorders Profile - Liquid Biopsy

This test is performed on cell-free DNA/RNA in peripheral blood plasma by sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A (MLL), KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. Test orders include summary interpretation of all results together.

Molecular
NeoLAB™ NPM1 Mutation Analysis - Liquid Biopsy

PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ NRAS Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ NRAS Mutation Analysis- Liquid Biopsy will only be performed for hematological diseases at this time.

Molecular
NeoLAB™ PML-RARA Translocation, t(15;17) - Liquid Biopsy

Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript using cell-free plasma DNA/RNA. Both long and short isoforms of the fusion transcript are detected.

Molecular
NeoLAB™ RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) - Liquid Biopsy

Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO) using cell-free plasma DNA/RNA.

Molecular
NeoTYPE AML Favorable-Risk Profile

This test is performed by sequencing of select exons of the genes FLT3 and KIT. Test orders include summary interpretation of all results together. Individual genes from a validated list of myeloid genes can be added-on.

Molecular
NeoTYPE AML Prognostic Profile

This test is performed by sequencing the entire coding regions of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53 and WT1. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. The AML Prognostic Profile may also be ordered as reflex after intermediate cytogenetics in the AML Reflex Panel (see separate AML Reflex Panel listing). For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.

Molecular
NeoTYPE Myeloid Disorders Profile

This test is performed by the sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2 including V617F and Exons 12+14, JAK3, KDM6A, KIT, KRAS, MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. CALR and FLT3 are performed by multiple methods. Test orders include summary interpretation of all results together.

Molecular
NPM1 MRD Analysis

NPM1 MRD Analysis is performed by PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations. Testing is performed on plasma with a PCR modification to improve sensitivity. The lower limit of detection of mutated NPM1 in this assay is 5 x 10^-3 (0.5%). Positive results are reported quantitatively if the percentage of mutated DNA is ≥1%, and they are reported qualitatively if ˂1%.    

Molecular
NPM1 Mutation Analysis

PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing may be performed on plasma to increase sensitivity.

Molecular
NRAS Exon 4 Mutation Analysis

Bi-directional sequencing of NRAS exon 4 is performed using PCR primers designed to target hotspot mutations in codons 117 and 146, among other regions in exon 4. Testing is available separately or in combination with BRAF, KRAS and HRAS in the RAS/RAF Panel.

Molecular
NRAS Mutation Analysis

Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61.

Molecular
NUP98

Disease(s): Acute Myeloid Leukemia
Probes: NUP98 (11p15.4)

FISH
PAX5Paired Box 5 (PAX5) is a B-cell specific activator protein (BSAP). In early stages of B-cell development, PAX5 influences the expression of several B-cell specific genes, such as CD19 and CD20. PAX5 is expressed primarily in pro-, pre-, and mature B-cells, but not in plasma cells. There is an excellent correlation between CD20 and PAX5 expression; however, anti-PAX5 exceeds the specificity and sensitivity of L26 (CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B-cells, including classic Hodgkin lymphoma. It is very specific to B-cell lineage and does not stain T-cells. Immunohistochemistry (IHC)
PML-RARA Translocation, t(15;17)

Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript. Both long and short isoforms of the fusion transcript are detected. Positive results identify the isoform and quantify it as a ratio with the amount of transcript from a normal control gene. Analytical sensitivity is 1 tumor cell in 100,000 normal cells.

Molecular
PTPN11 Mutation Analysis

Bi-directional sequencing of exons 2-4 of PTPN11.

Molecular
RUNX1 Mutation Analysis

Bi-directional sequencing of exons 4-10 of the RUNX1 gene

Molecular
RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21)

Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results are reported as a ratio between quantities of (8;21) transcript and a normal control gene.

Molecular
RUNX1T1/RUNX1 (ETO/AML1) t(8;21)Probes: RUNX1T1/RUNX1 (ETO/AML1) t(8;21)
Disease(s): AML-M2
FISH
SETBP1 Mutation Analysis

Bi-directional sequencing of the SETBP1 exon 4 mutation hotspot (covering amino acids 823-941). The locked nucleic acid (LNA) technique is used to increase detection sensitivity for mutations at D868, G870, I871, and D880.

Molecular
SF3B1 Mutation Analysis

RT-PCR and bi-directional sequencing of exons 14-17 of the SF3B1 gene. More than 90% of reported mutations are detected in these exons. This test detects mutations present at 10-15% or more in a wild-type background.

Molecular
SRSF2 Mutation Analysis

Bi-directional sequencing of the mutation hotspot region in exon 1 of the SRSF2 gene corresponding to amino acids 57-120.

Molecular
Standard Leukemia/Lymphoma Panel - 24 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.

Flow Cytometry
TET2 Mutation Analysis

Bi-directional sequencing of the entire coding sequence of the TET2 transcript variant A (2002 amino acids in length).

Molecular
TP53 Mutation Analysis

Bi-directional sequencing of TP53 exons 4-9.

Molecular
U2AF1 Mutation Analysis

Bi-directional sequencing of exons 2 and 7 of the U2AF1 gene (also called U2AF35).

Molecular
Universal Fusion/Expression Profile

The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.

Molecular
Wright GiemsaSpecial stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology. Immunohistochemistry (IHC)
WT1 Mutation Analysis

Bi-directional sequencing of exons 7 and 9 is performed for detection of sequence variant mutations.  Fragment analysis of exon 7 is also performed for enhanced detection of heterozygous insertion/deletion mutations. The SNP genotype at rs16754 is reported.  Testing is performed on plasma for increased sensitivity whenever possible.    

Molecular
ZRSR2 Mutation Analysis

Bi-directional sequencing of exons 5 and 7-11 of the ZRSR2 gene.

Molecular